AIMS: Cardiovascular risk scores in @entity6 are common, but renal risk scores less so. Rarely has a combined risk score been formulated, yet this would be useful both to physicians and health-care funders. MATERIALS AND METHODS: Data were derived from the ADVANCE-ON study, a randomized controlled trial (of 5 years mean duration) with a post-randomization follow-up (mean 4.9   years), amongst 11,140 high-risk @entity1 with @entity6 . The outcome analysed was the occurrence of either @entity8 . A Cox regression model was used to determine weightings in the risk score. The resultant score was recalibrated to each of three major global regions, as covered by the ADVANCE-ON study. RESULTS: Over a median of 9.9   years, 1145 @entity1 experienced at least one component of the combined outcome event. The resultant, AD-ON risk score, incorporated 13 demographic or clinical variables. Its discrimination was modest (c-statistic   =   0.668; 95% confidence interval (0.651, 0.685)) but its calibration was excellent (predicted and observed risks coincided well, within disparate global regions). In terms of the integrated discrimination improvement, its performance was marginally superior, over a 10-year risk horizon, to existing risk scores in clinical use, from a restricted version of the same data, for macrovascular and @entity8 separately. CONCLUSIONS: The AD-ON risk score has advantages over existing vascular risk scores in @entity6 from ADVANCE which treat macrovascular and @entity8 separately, including its simplicity of use and global application.

Prediction of ten-year vascular risk amongst XXXX with @entity6 : the AD-ON risk score.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal diseases', 'renal disease', 'fatal or non-fatal macrovascular or renal disease'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']
@entity1 :: (9606,Species) :: ['patients']
